Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

ABSTRACT: Imlifidase is a cysteine proteinase which specifically cleaves IgG, inhibiting Fc-mediated effector function within hours of administration. Imlifidase converts a positive crossmatch to a potential donor (T cell, B cell, or both), to negative, enabling transplantation to occur between previously HLA incompatible donor-recipient pairs. To date, 39 crossmatch positive patients received imlifidase prior to a kidney transplant in four single-arm, open-label, phase 2 studies. At 3 years, for patients who were AMR+ compared to AMR-, death-censored allograft survival was 93% vs 77%, patient survival was 85% vs 94%, and mean eGFR was 49 ml/min/1.73 m² vs 61 ml/min/1.73 m² , respectively. The incidence of AMR was 38% with most episodes occurring within the first month post-tra

SUBMITTER: Kjellman C 

PROVIDER: S-EPMC9290474 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature